Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
설정
언어
한국어
통화
USD
테마
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
주식 순위 #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
주가
$0.5275
시가총액
$1.25M
변동 (1일)
-3.56%
변동 (1년)
-83.77%
국가
US
거래 Ensysce Biosciences, Inc. (ENSC)

카테고리

Healthcare
Ensysce Biosciences, Inc. (ENSC)의 발행 주식 수
September 2025 기준 발행 주식 수: 2.89M
Ensysce Biosciences, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 2.89M입니다. December 2023 말 기준 회사는 2.26M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Ensysce Biosciences, Inc. (ENSC)의 발행 주식 수 기록 (2017 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
2026 (TTM) 2.89M 65.20%
2024 1.75M -22.84%
2023 2.26M 1,158.25%
2022 179.93K 114.16%
2021 84.02K -98.12%
2020 4.46M -26.81%
2019 6.09M 1.42%
2018 6.01M 0.37%
2017 5.98M 0.00%
유사 기업 또는 경쟁사의 발행 주식 수
회사 발행 주식 수 차이 국가
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 154,015.04%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 8,697.46%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M 3,465.42%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 6,483.27%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 16,655.56%
AU